M.V.I.-12 Lyophilized

   
Google
 
Web NewDrugInformation.com

M.V.I.-12 Lyophilized


Drug - M.V.I.-12 Lyophilized
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Ascorbic Acid; Biotin; Cyanocobalamin; Dexpanthenol; Ergocalciferol; Folic Acid; Niacinamide; Pyridoxine; Riboflavin Phosphate Sodium; Thiamine; Vitamin A; Vitamin E
Multiple ingredients are in alphabetical order.

Strength - 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL
The potency of the active ingredient(s), Ascorbic Acid; Biotin; Cyanocobalamin; Dexpanthenol; Ergocalciferol; Folic Acid; Niacinamide; Pyridoxine; Riboflavin Phosphate Sodium; Thiamine; Vitamin A; Vitamin E. May repeat for multiple part products.

Applicant - ASTRAZENECA
The firm name holding legal responsibility for M.V.I.-12 Lyophilized. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 018933
The FDA assigned number to M.V.I.-12 Lyophilized. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify M.V.I.-12 Lyophilized. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Aug 8, 1985
The date M.V.I.-12 Lyophilized was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of M.V.I.-12 Lyophilized. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs M.V.I.-12 Lyophilized is in. Format is RX, OTC, DISCN.

Applicant Full Name - Astrazeneca Lp
The full name of the firm holding legal responsibility for the new application of M.V.I.-12 Lyophilized.

M.V.I.-12 Lyophilized


Mvc Plus 10mg/ml;0.006mg/ml;0.5ugm/ml;1.5mg/ml;20 Iu/ml;0.04mg/ml;4mg/ml;0.4mg/ml;0.36mg/ml;0.3mg/ml;330 Units/ml;1 Iu/ml Injectable; Injection
M.V.I. Adult 200mg/vial;0.06mg/vial;0.005mg/vial;15mg/vial;0.005mg/vial;0.6mg/vial;40mg/vial;6mg/vial;3.6mg/vial;6mg/vial;1mg/vial;10mg/vial;0.15mg/vial Injectable; Iv (infusion)
M.V.I. Adult (pharmacy Bulk Package) 200mg/5ml;0.06mg/5ml;0.005mg/5ml;15mg/5ml;0.005mg/5ml;0.6mg/5ml;40mg/5ml;6mg/5ml;3.6mg/5ml;6mg/5ml;1mg/5ml;10mg/5ml;0.15mg/5ml Injectable; Iv (infusion)
M.V.I.-12 20mg/ml;0.006mg/ml;0.5ugm/ml;1.5mg/ml;20 Iu/ml;0.6mg/ml;4mg/ml;0.4mg/ml;0.36mg/ml;0.6mg/ml;330 Units/ml;1 Iu/ml Injectable; Injection
M.V.I.-12 Lyophilized 100mg/vial;0.06mg/vial;0.005mg/vial;15mg/vial;5ugm/vial;0.4mg/vial;40mg/vial;4mg/vial;3.6mg/vial;3mg/vial;1mg/vial;10mg/vial Injectable; Injection
M.V.I. Pediatric 80mg/vial;0.02mg/vial;0.001mg/vial;5mg/vial;0.01mg/vial;0.14mg/vial;17mg/vial;0.2mg/vial;1mg/vial;1.4mg/vial;eq 1.2mg Base/vial;0.7mg/vial;7mg/vial For Solution; Iv (infusion)
Berocca Pn 50mg/ml;0.03mg/ml;0.0025mg/ml;7.5mg/ml;100 Iu/ml;0.2mg/ml;20mg/ml;2mg/ml;1.8mg/ml;1.5mg/ml;1,650 Iu/ml;5 Iu/ml Injectable; Injection
M.V.C. 9+3 10mg/ml;0.006mg/ml;0.5ugm/ml;1.5mg/ml;20 Iu/ml;0.04mg/ml;4mg/ml;0.4mg/ml;0.36mg/ml;0.3mg/ml;330 Units/ml;1 Iu/ml Injectable; Injection
M.V.I.-12 10mg/ml;0.006mg/ml;0.5ugm/ml;1.5mg/ml;20 Iu/ml;0.04mg/ml;4mg/ml;0.4mg/ml;0.36mg/ml;0.3mg/ml;330 Units/ml;1 Iu/ml Injectable; Injection
M.V.I.-12 (without Vitamin K) 20mg/ml;0.006mg/ml;0.05ugm/ml;1.5mg/ml;0.0005mg/ml;0.06mg/ml;4mg/ml;0.6mg/ml;0.36mg/ml;0.6mg/ml;0.1mg/ml;1mg/ml Injectable; Injection

NewDrugInformation